Wednesday, August 25, 2021 | 11am EDT | 8am PDT | 5pm CET
Click here to register for FREE!
Event Overview
The development of Allogeneic Cell Therapies is vastly different than traditional biopharmaceutical products, including other cell and gene therapy products, and the complexities of this novel therapeutic treatment span the development pipeline.
With the increasing prevalence of allogeneic cell transplantation (allo-HCT), the importance of securing a cellular product safely from a donor, and ensuring that the product is without additional risk to the recipient, continues to be of critical importance.
Please join industry leaders from Eurofins VRL and Eurofins BioPharma Product Testing as we share our expertise in testing allo-HCT for routine collection and storage of cells for use in transplantation, immune therapies and other medically-validated indications.
During this webinar, our experts will discuss:
- Required testing for donor source cells: Infectious Disease
- Relevant donor source testing: Sterility, Endotoxin, Mycoplasma
- Determining Eligibility
- Post cell processing/manufacturing GMP biosafety testing
- The need to repeat the infectious disease testing
- Specialized testing based upon raw materials/reagents used in cell processing
- Relevant testing and why it is performed
- Technical and regulatory considerations
Presenters:
 | Stanley Prince Senior Scientific Advisor, Biologics Eurofins BioPharma Product Testing |
 | Kimberly Elliott Director of Business Development Eurofins VRL |
Click here to register for FREE!
